Developments in factor Xa inhibitors for the treatment of thromboembolic disorders

Medicinal Research Reviews

Volumn 31, Issue 2, 2011, Pages 202-283

  Lee, Yu Kai ^a   Player, Mark R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anticoagulant; Factor Xa; Factor Xa inhibitor; FXa; FXa inhibitor

Indexed keywords

2 AMINOBENZAMIDE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CAPROLACTAM DERIVATIVE; CLOPIDOGREL; COUMARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; ISOXAZOLE DERIVATIVE; ISOXAZOLINE DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; PHENYLENEDIAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDONE DERIVATIVE; PROTHROMBIN; PYRAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; TICLOPIDINE; TINZAPARIN; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; ENZYME INHIBITION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; THROMBOEMBOLISM;

EID: 79551573812     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20183     Document Type: Article

References (249)

1. Beaglehole R, Bonita R. Global public health: A scorecard. Lancet 2008;372:1988-1996.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
3. Goldhaber SZ, Morrison RB. Pulmonary embolism and deep vein thrombosis. Circulation 2002;106:1436-1438.
4. Dickson BC. Venous thrombosis: On the history of Virchow's triad. U Toronto Med J 2004;31:166-171.
5. Bagot CN, Arya R. Virchow and his triad: A question of attribution. Br J Haematol 2008;143:180-190.
6. Chung I, Lip GYH. Virchow's triad revisited: Blood constituents. Pathophysiol Haemost Thromb 2003/2004;33:449-454.
7. Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic. Curr Top Med Chem 2005;5:1677-1695.
8. Scarborough RM, Pandey A, Zhang X. Small molecule anticoagulant/antithrombotic agents. Ann Rep Med Chem 2005;40:85-99.
9. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-855.
10. Ieko M, Tarumi T, Nakabayashi T, Yoshida M, Naito S, Koike T. Factor Xa inhibitors: New anti-thrombotic agents and their characteristics. Front Biosci 2006;11:232-248.
11. Eriksson BI, Quinlan DJ. Oral anticoagulants in development: Focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006;66:1411-1429.
12. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3-19.
13. Preželj A, Anderluh PŠ, Peternel L, Urleb U. Recent advances in serine protease inhibitors as anticoagulant agents. Curr Pharm Design 2007;13:287-312.
14. Turpie AGG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-1247.
15. Turpie AGG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008;29:155-165.
16. Turpie AGG. Direct factor Xa and direct thrombin inhibitors: A clinical trial update. Curr Opin Drug Disc Dev 2009;12:497-508.
17. Steffel J, Lüscher TF. Novel anticoagulants in clinical development: Focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med 2009;10:616-623.
18. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22.
19. Lassen MR. Recent developments in the use of oral anticoagulants. Expert Opin Pharmacother 2009;10:1769-1781.
20. Casimiro-Garcia A, Dudley DA, Heemstra RJ, Filipski KJ, Bigge CF, Edmunds JJ. Progress in the discovery of factor Xa inhibitors. Expert Opin Ther Pat 2006;16:119-145.
21. Kasani A, Subedi R, Stier M, Holsworth DD, Maiti SN. Cardiovascular agents: Renin inhibitors and factor Xa inhibitors. Heterocycles 2007;73:47-85.
22. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008;14:1152-1175.
23. Beck EA. The chemistry of blood coagulation: A summary by Paul Morawitz (1905). Thromb Haemost 1977;37:376-379.
24. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964;202:498-499.
25. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
26. Riddel JP, Jr, Aouizerat BE, Miaskowski C, Lillicrap DP. Theories of blood coagulation. J Pediatr Oncol Nurs 2007;24:123-131.
27. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30:10363-10370.
28. Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. J Biol Chem 2003;278:50819-50832.
29. Kitchen S, Makris M. Laboratory tests of hemostasis. In: O'Shaughnessy D, Makris M, Lillicrap D, editors. Practical hemostasis and thrombosis. 1st ed. Oxford, UK: Blackwell Publishing; 2007. pp 8-17.
30. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26:41-48.
31. Hoffman M, Monroe DM. Rethinking the coagulation cascade. Curr Hematol Rep 2005;4:391-396.
32. O'Connell NM. Basic principles underlying the coagulation system. In: O'Shaughnessy D, Makris M, Lillicrap D, editors. Practical hemostasis and thrombosis. 1st ed. Oxford, UK: Blackwell Publishing; 2007. pp 1-7.
33. Fedan JS. Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) drugs. In: Craig CR, Stitzel RE, editors. Modern pharmacology with clinical applications. 6th ed. Baltimore, Maryland: Lippincott Williams and Wilkins; 2004.
34. El-Gengaihy AE, Abdelhadi SI, Kirmani JF, Qureshi AI, John BT, David JT. Thrombolytics. Comprehensive medicinal chemistry II. Oxford, UK: Elsevier; 2007. pp 763-781.
35. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494.
36. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Haematol 2008;142:515-528.
37. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:199S-233S.
38. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008;100:530-547.
39. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:160S-198S.
40. Link KP. The discovery of dicumarol and its sequels. Circulation 1959;19:97-107.
41. Ansell J. Factor Xa or thrombin: Is factor Xa a better target? J Thromb Haemost 2007;5:60-64.
42. Büller HR. Factor Xa is a superior target to factor IIa for antithrombotic therapies. Semin Thromb Hemost 2003;29:37-38.
43. Schulman S. Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation? Semin Thromb Hemost 2003;29:33-36.
44. Weitz JI. Factor Xa or thrombin: Is thrombin a better target? J Thromb Haemost 2007;5:65-67.
45. Leadley RJ, Jr. Coagulation factor Xa inhibition: Biological background and rationale. Curr Top Med Chem 2001;1:151-159.
46. Srivastava S, Goswami LN, Dikshit DK. Progress in the design of low molecular weight thrombin inhibitors. Med Res Rev 2005;25:66-92.
47. Agrawal YK, Vaidya H, Bhatt H, Manna K, Brahmkshatriya P. Recent advances in the treatment of thromboembolic diseases: Venous thromboembolism. Med Res Rev 2007;27:891-914.
48. Page MJ, Macgillivray RTA, Di Cera E. Determinants of specificity in coagulation proteases. J Thromb Haemost 2005;3:2401-2408.
49. Rai R, Sprengeler PA, Elrod KC, Young WB. Perspectives on factor Xa inhibition. Curr Med Chem 2001;8:101-119.
50. Liebeschuetz JW, Jones SD, Wiley ME, Young SC. Iterative structure-based screening of virtual chemical libraries and factor Xa: Finding the orally available antithrombotic candidate LY517717. In: Hubbard RE, editor. Structure-based drug discovery. Cambridge, UK: Royal Society of Chemistry; 2006. pp 173-192.
51. Stubbs II MT. Structural aspects of factor Xa inhibition. Curr Pharm Des 1996;2:543-552.
52. Stubbs MT, Bode W. Structure and specificity in coagulation and its inhibition. Trends Cardiovasc Med 1995;5:157-166.
53. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(1-45) factor Xa at 2.2Å resolution. J Mol Bio 1993;232:947-966.
54. Brandstetter H, Kuhne A, Bode W, Huber R, von der Saal W, Wirthensohn K, Engh RA. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996;271:29988-29992.
55. Kamata K, Kawamoto H, Honma T, Iwama T, Kim S-H. Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci USA 1998;95:6630-6635.
56. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-162.
57. Desai UR. New antithrombin-based anticoagulants. Med Res Rev 2004;24:151-181.
58. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90:1-7.
59. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008;99:807-848.
60. Mulloy B, Gray E, Barrowcliffe TW. Characterization of unfractionated heparin: Comparison of materials from the last 50 years. Thromb Haemost 2000;84:1052-1056.
61. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. Chest 2008;133:141S-159S.
62. Antignani PL, Goffredo C, Pepe LL, Allegra C. Low-molecular-weight-heparins: A review of literature. Vasc Dis Prev 2008;5:190-199.
63. Pineo GF, Hull RD. Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother 2003;4:2355-2362.
64. Hull RD, Pineo GF. Dalteparin sodium. Expert Opin Pharmacother 2001;2:1325-1337.
65. Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-497.
66. Mason JA, Turpie AGG. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opin Pharmacother 2002;3:575-598.
67. Org-10172. Drugs Fut 1987;12:131-133.
68. Acostamadiedo JM, Iyer UG, Owen J. Danaparoid sodium. Expert Opin Pharmacother 2000;1:803-814.
69. Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992;22:58-65.
70. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: Treatment options and special considerations. Pharmacotherapy 2007;27:564-587.
71. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: The discovery of the antithrombin binding site. Biochimie 2003;85:83-89.
72. Choay J, Lormeau J-C, Petitou M. Low molecular weight oligosaccharides active in plasma against factor Xa. Ann Pharm Fr 1981;39:37-44.
73. Petitou M, van Boeckel CAA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed 2004;43:3118-3133.
74. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics. Angew Chem Int Ed 1993;32:1671-1690.
75. Beetz T, van Boeckel CAA. Synthesis of an antithrombin binding heparin-like pentasaccharide lacking 6-O sulphate at its reducing end. Tetrahedron Lett 1986;27:5889-5892.
76. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinaÿ P, Jacquinet J-C, Torri G. Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(β-D-glucopyranosyluronic acid)-(1→4)-O-(2-deoxy-2-sulfamido-3, 6-di-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res 1986;147:221-236.
77. Petitou M, Duchaussoy P, Lederman I, Choay J, Jacquinet J-C, Sinaÿ P, Torri G. Synthesis of heparin fragments: A methyl α-pentaoside with high affinity for antithrombin III. Carbohydr Res 1987;167:67-75.
78. Turpie AGG. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 2004;5:1373-1384.
79. Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005;14:847-858.
80. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997;94:14683-14688.
81. van Boeckel CAA, Beetz T, van Aelst SF. Synthesis of a potent antithrombin activating pentasaccharide: A new heparin-like fragment containing two 3-O-sulphated glucosamines. Tetrahedron Lett 1988;29:803-806.
82. Basten J, Jaurand G, Olde-Hanter B, Duchaussoy P, Petitou M, van Boeckel CAA. Biologically active heparin-like fragments with a "non-glycosamino" glycan structure. Part 3: O-Alkylated-O-sulphated pentasaccharides. Bioorg Med Chem Lett 1992;2:905-910.
83. Westerduin P, van Boeckel CAA, Basten JEM, Broekhoven MA, Lucas H, Rood A, van der Heijden H, van Amsterdam RGM, van Dinther TG, Meuleman DG, Visser A, Vogel GMT, Damm JBL, Overklift GT. Feasible synthesis and biological properties of six "non-glycosamino" glycan analogues of the antithrombin III binding heparin pentasaccharide. Bioorg Med Chem 1994;2:1267-1280.
84. Diaz-Ricart M, del Fresno M. Idraparinux sodium. Drugs Fut 2002;27:639-644.
85. Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L. Idraparinux: Review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 2008;17:773-777.
86. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008;28:380-386.
87. Bianchini P, Liverani L, Spelta F, Mascellani G, Parma B. Variability of heparins and heterogeneity of low molecular weight heparins. Semin Thromb Hemost 2007;33:496-502.
88. Schwartz LB. Heparin comes clean. N Engl J Med 2008;358:2505-2509.
89. Petitou M, Barzu T, Herault J-P, Herbert J-M. A unique trisaccharide sequence in heparin mediates the early step of antithrombin III activation. Glycobiology 1997;7:323-327.
90. Gunnarsson GT, Desai UR. Interaction of designed sulfated flavanoids with antithrombin: Lessons on the design of organic activators. J Med Chem 2002;45:4460-4470.
91. Raghuraman A, Liang A, Krishnasamy C, Lauck T, Gunnarsson GT, Desai UR. On designing non-saccharide, allosteric activators of antithrombin. Eur J Med Chem 2009;44:2626-2631.
92. Monien BH, Desai UR. Antithrombin activation by nonsulfated, non-polysaccharide organic polymer. J Med Chem 2005;48:1269-1273.
93. Monien BH, Cheang KI, Desai UR. Mechanism of poly(acrylic acid) acceleration of antithrombin inhibition of thrombin: Implications for the design of novel heparin mimics. J Med Chem 2005;48:5360-5368.
94. Monien BH, Henry BL, Raghuraman A, Hindle M, Desai UR. Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg Med Chem 2006;14:7988-7998.
95. Henry BL, Monien BH, Bock PE, Desai UR. A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 2007;282:31891-31899.
96. Ledizet M, Harrison LM, Koski RA, Cappello M. Discovery and pre-clinical development of antithrombotics from hematophagous invertebrates. Curr Med Chem Cardiovasc Hematol Agents 2005;3:1-10.
97. Koh CY, Kini RM. Anticoagulants from hematophagous animals. Expert Rev Hematol 2008;1:135-139.
98. Urata J, Shojo H, Kaneko Y. Inhibition mechanisms of hematophagous invertebrate compounds acting on the host blood coagulation and platelet aggregation pathways. Biochimie 2003;85:493-500.
99. Michel S. Anticoagulants and inhibitors of platelet aggregation derived from leeches. FEBS Lett 2001;492:187-192.
100. Ewing WR, Pauls HW, Spada AP. Progress in the design of inhibitors of coagulation factor Xa. Drugs Fut 1999;24:771-787.
101. Zhu B-YZ, Huang W, Su T, Marlowe C, Sinha U, Hollenbach S, Scarborough RM. Discovery of transition state factor Xa inhibitors as potential anticoagulant agents. Curr Top Med Chem 2001;1:101-119.
102. Sanderson PEJ. Anticoagulants: Inhibitors of thrombin and factor Xa. Ann Rep Med Chem 2001;36:79-88.
103. Sanderson PEJ. Small, noncovalent serine protease inhibitors. Med Res Rev 1999;19:179-197.
104. Huang W, Naughton MA, Yang H, Su T, Dam S, Wong PW, Arfsten A, Edwards S, Sinha U, Hollenbach S, Scarborough RM, Zhu B-Y. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors. Bioorg Med Chem Lett 2003;13:723-728.
105. Su T, Yang H, Volkots D, Woolfrey J, Dam S, Wong P, Sinha U, Scarborough RM, Zhu B-Y. Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors. Bioorg Med Chem Lett 2003;13:729-732.
106. Markwardt F, Landmann H, Walsmann P. Comparative studies on the inhibition of trypsin, plasmin, and thrombin by derivatives of benzylamine and benzamidine. Eur J Biochem 1968;6:502-506.
107. Geratz JD, Cheng MCF, Tidwell RR. Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement. J Med Chem 1976;19:634-639.
108. Geratz JD, Whitmore AC, Cheng MCF, Piantadosi C. Diamidino-α, ω-diphenoxyalkanes. Structure-activity relations for the inhibition of thrombin, pancreatic kallikrein, and trypsin. J Med Chem 1973;16:970-975.
109. Tidwell RR, Geratz JD, Dann O, Volz G, Zeh D, Loewe H. Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases. J Med Chem 1978;21:613-623.
110. Stürzebecher J, Markwardt F, Walsmann P. Synthetic inhibitors of serine proteinases XIV. Inhibition of factor Xa by derivatives of benzamidine. Thromb Res 1976;9:637-646.
111. Tidwell RR, Webster WP, Shaver SR, Geratz JD. Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors. Thromb Res 1980;19:339-349.
112. Stürzebecher O, Markwardt F, Walsmann P. Synthetic inhibitors of serine proteinases XXIII. Inhibition of factor Xa by diamidines. Thromb Res 1980;17:545-548.
113. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994;71:314-319.
114. Nagahara T, Yokoyama Y, Inamura K, Katakura S-I, Komoriya S, Yamaguchi H, Hara T, Iwamoto M. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1994;37:1200-1207.
115. Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EAAML, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: Results of the XaNADU-ACS trial. J Thromb Haemost 2005;3:439-447.
116. Hirayama F, Koshio H, Katayama N, Kurihara H, Taniuchi Y, Sato K, Hisamichi N, Sakai-Moritani Y, Kawasaki T, Matsumoto Y, Yanagisawa I. The discovery of YM-60828: A potent, selective and orally-bioavailable factor Xa inhibitor. Bioorg Med Chem 2002;10:1509-1523.
117. Koshio H, Hirayama F, Ishihara T, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S-i. Synthesis and biological activity of novel 1, 4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem 2004;12:2179-2191.
118. Hirayama F, Koshio H, Katayama N, Ishihara T, Kaizawa H, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kurihara H, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S-i. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: Potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template. Bioorg Med Chem 2003;11:367-381.
119. Huang W, Zhang P, Zuckett JF, Wang L, Woolfrey J, Song Y, Jia ZJ, Clizbe LA, Su T, Tran K, Huang B, Wong P, Sinha U, Park G, Reed A, Malinowski J, Hollenbach SJ, Scarborough RM, Zhu B-Y. Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors. Bioorg Med Chem Lett 2003;13:561-566.
120. Shaw KJ, Guilford WJ, Dallas JL, Koovakkaat SK, McCarrick MA, Liang A, Light DR, Morrissey MM. (Z, Z)-2, 7-Bis(4-amidinobenzylidene)cycloheptan-1-one: Identification of a highly active inhibitor of blood coagulation factor Xa. J Med Chem 1998;41:3551-3556.
121. Galemmo RA Jr, Maduskuie TP, Dominguez C, Rossi KA, Knabb RM, Wexler RR, Stouten PFW. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial SAR studies. Bioorg Med Chem Lett 1998;8:2705-2710.
122. Phillips GB, Buckman BO, Davey DD, Eagen KA, Guilford WJ, Hinchman J, Ho E, Koovakkat S, Liang A, Light DR, Mohan R, Ng HP, Post JM, Shaw KJ, Smith D, Subramanyam B, Sullivan ME, Trinh L, Vergona R, Walters J, White K, Whitlow M, Wu S, Xu W, Morrissey MM. Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem 1998;41:3557-3562.
123. Sinha U. ZK-807834 Berlex. Curr Opin Investig Drugs 2002;3:1736-1741.
124. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005;1:71-104.
125. Adler M, Davey DD, Phillips GB, Kim S-H, Jancarik J, Rumennik G, Light DR, Whitlow M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with Factor Xa. Biochemistry 2000;39:12534-12542.
126. Sagi K, Nakagawa T, Yamanashi M, Makino S, Takahashi M, Takayanagi M, Takenaka K, Suzuki N, Oono S, Kataoka N, Ishikawa K, Shima S, Fukuda Y, Kayahara T, Takehana S, Shima Y, Tashiro K, Yamamoto H, Yoshimoto R, Iwata S, Tsuji T, Sakurai K, Shoji M. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids. J Med Chem 2003;46:1845-1857.
127. Zhang P, Zuckett JF, Woolfrey J, Tran K, Huang B, Wong P, Sinha U, Park G, Reed A, Malinowski J, Hollenbach S, Scarborough RM, Zhu B-Y. Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors. Bioorg Med Chem Lett 2002;12:1657-1661.
128. Ueno H, Yokota K, Hoshi Ji, Yasue K, Hayashi M, Hase Y, Uchida I, Aisaka K, Katoh S, Cho H. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring. J Med Chem 2005;48:3586-3604.
129. Noguchi T, Tanaka N, Nishimata T, Goto R, Hayakawa M, Sugidachi A, Ogawa T, Asai F, Matsui Y, Fujimoto K. Indoline derivatives I: Synthesis and factor Xa (fXa) inhibitory activities. Chem Pharm Bull 2006;54:163-174.
130. Noguchi T, Tanaka N, Nishimata T, Goto R, Hayakawa M, Sugidachi A, Ogawa T, Asai F, Ozeki T, Fujimoto K. Indoline derivatives II: Synthesis and factor Xa (fXa) inhibitory activities. Chem Pharm Bull 2007;55:393-402.
131. Noguchi T, Tanaka N, Nishimata T, Goto R, Hayakawa M, Sugidachi A, Ogawa T, Asai F, Fujimoto K. Cinnamylindoline derivatives: Synthesis and factor Xa (fXa) inhibitory activities. Chem Pharm Bull 2007;55:1494-1504.
132. Noguchi T, Tanaka N, Nishimata T, Goto R, Hayakawa M, Sugidachi A, Ogawa T, Asai F, Fujimoto K. Cinnamyl derivatives: Synthesis and factor Xa (fXa) inhibitory activities. Chem Pharm Bull 2008;56:758-770.
133. Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 2000;455:29-60.
134. Noguchi T, Tanaka N, Nishimata T, Goto R, Hayakawa M, Sugidachi A, Ogawa T, Niitsu Y, Asai F, Ishizuka T, Fujimoto K. Discovery of R-142086 as a factor Xa (fXa) inhibitor: Syntheses and structure-activity relationships of cinnamyl derivatives. Chem Pharm Bull 2009;57:22-33.
135. Maduskuie TP, McNamara KJ, Ru Y, Knabb RM, Stouten PFW. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. J Med Chem 1998;41:53-62.
136. Quan ML, Pruitt JR, Ellis CD, Liauw AY, Galemmo RA, Jr, Stouten PFW, Wityak J, Knabb RM, Thoolen MJ, Wong PC, Wexler RR. Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997;7:2813-2818.
137. Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL, Huang PP, Harrison K, Knabb RM, Thoolen MJ, Wong PC, Wexler RR. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. J Med Chem 1999;42:2752-2759.
138. Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G, Wright MR, Wong PC, Wexler RR. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. J Med Chem 1999;42:2760-2773.
139. Pruitt JR, Pinto DJ, Estrella MJ, Bostrom LL, Knabb RM, Wong PC, Wright MR, Wexler RR. Isoxazolines and isoxazoles as factor Xa inhibitors. Bioorg Med Chem Lett 2000;10:685-689.
140. Pinto DJP, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PYS. Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)-[1, 1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001;44:566-578.
141. Wong PC, Pinto DJ, Knabb RM. Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 2002;20:137-152.
142. Taglialatela M. DPC-423. Curr Opin Investig Drugs 2002;3:252-254.
143. Pruitt JR, Pinto DJP, Galemmo RA, Jr, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PYS, Wexler RR. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2'-(aminosulfonyl)[1, 1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2003;46: 5298-5315.
144. Lam PYS, Clark CG, Li R, Pinto DJP, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR. Structure-based design of novel guanidine/benzamidine mimics: Potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J Med Chem 2003;46: 4405-4418.
145. Quan ML, Lam PYS, Han Q, Pinto DJP, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005;48:1729-1744.
146. Quan ML, Han Q, Fevig JM, Lam PYS, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett 2006;16:1795-1798.
147. Lessen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomized, double blind, five-arm, parallel group, dose response study of a new oral directly acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003;102:15a, Abstract 41.
148. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs. Chest 2008;133:234S-256S.
149. Fevig JM, Cacciola J, Buriak J, Jr, Rossi KA, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PYS. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4, 3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa. Bioorg Med Chem Lett 2006;16:3755-3760.
150. Pinto DJP, Orwat MJ, Quan ML, Han Q, Galemmo RA Jr, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PYS. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1, 1']-biphen-4-yl]-1, 4, 5, 6-tetrahydropyrazolo-[3, 4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett 2006;16:4141-4147.
151. Li Y-L, Fevig JM, Cacciola J, Buriak J, Jr, Rossi KA, Jona J, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PYS. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4, 3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa. Bioorg Med Chem Lett 2006;16:5176-5182.
152. Pinto DJP, Galemmo RA, Jr, Quan ML, Orwat MJ, Clark C, Li R, Wells B, Woerner F, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, He K, Wexler RR, Lam PYS. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties. Bioorg Med Chem Lett 2006;16:5584-5589.
153. Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJP, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PYS. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett 2007;17:1432-1437.
154. Varnes JG, Wacker DA, Jacobson IC, Quan ML, Ellis CD, Rossi KA, He MY, Luettgen JM, Knabb RM, Bai S, He K, Lam PYS, Wexler RR. Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorg Med Chem Lett 2007;17:6481-6488.
155. Lee Y-K, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR. 7-Fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem 2008;51:282-297.
156. Varnes JG, Wacker DA, Pinto DJP, Orwat MJ, Theroff JP, Wells B, Galemmo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PYS, Wexler RR. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett 2008;18:749-754.
157. Pinto DJP, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PYS. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-5356.
158. Carreiro J, Ansell J. Apixaban, an oral direct factor Xa inhibitor: Awaiting the verdict. Expert Opin Investig Drugs 2008;17:1937-1945.
159. Qiao JX, Cheney DL, Alexander RS, Smallwood AM, King SR, He K, Rendina AR, Luettgen JM, Knabb RM, Wexler RR, Lam PYS. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of factor Xa. Bioorg Med Chem Lett 2008;18:4118-4123.
160. Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PYS. Highly efficacious factor Xa inhibitors containing a-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett 2009;19:462-468.
161. Ewing WR, Becker MR, Manetta VE, Davis RS, Pauls HW, Mason H, Choi-Sledeski YM, Green D, Cha D, Spada AP, Cheney DL, Mason JS, Maignan S, Guilloteau J-P, Brown K, Colussi D, Bentley R, Bostwick J, Kasiewski CJ, Morgan SR, Leadley RJ, Dunwiddie CT, Perrone MH, Chu V. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem 1999;42:3557-3571.
162. Becker MR, Ewing WR, Davis RS, Pauls HW, Ly C, Li A, Mason HJ, Choi-Sledeski YM, Spada AP, Chu V, Brown KD, Colussi DJ, Leadley RJ, Bentley R, Bostwick J, Kasiewski C, Morgan S. Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. Bioorg Med Chem Lett 1999;9:2753-2758.
163. Choi-Sledeski YM, McGarry DG, Green DM, Mason HJ, Becker MR, Davis RS, Ewing WR, Dankulich WP, Manetta VE, Morris RL, Spada AP, Cheney DL, Brown KD, Colussi DJ, Chu V, Heran CL, Morgan SR, Bentley RG, Leadley RJ, Maignan S, Guilloteau J-P, Dunwiddie CT, Pauls HW. Sulfonamidopyrrolidinone factor Xa inhibitors: Potency and selectivity enhancements via P-1 and P-4 optimization. J Med Chem 1999;42:3572-3587.
164. Choi-Sledeski YM, Becker MR, Green DM, Davis R, Ewing WR, Mason HJ, Ly C, Spada A, Liang G, Cheney D, Barton J, Chu V, Brown K, Colussi D, Bentley R, Leadley R, Dunwiddie C, Pauls HW. Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa. Bioorg Med Chem Lett 1999;9:2539-2544.
165. Gong Y, Becker M, Choi-Sledeski YM, Davis RS, Salvino JM, Chu V, Brown KD, Pauls HW. Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors. Bioorg Med Chem Lett 2000;10:1033-1036.
166. Watson NS, Brown D, Campbell M, Chan C, Chaudry L, Convery MA, Fenwick R, Hamblin JN, Haslam C, Kelly HA, King NP, Kurtis CL, Leach AR, Manchee GR, Mason AM, Mitchell C, Patel C, Patel VK, Senger S, Shah GP, Weston HE, Whitworth C, Young RJ. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. Bioorg Med Chem Lett 2006;16:3784-3788.
167. Young RJ, Campbell M, Borthwick AD, Brown D, Burns-Kurtis CL, Chan C, Convery MA, Crowe MC, Dayal S, Diallo H, Kelly HA, Paul King N, Kleanthous S, Mason AM, Mordaunt JE, Patel C, Pateman AJ, Senger S, Shah GP, Smith PW, Watson NS, Weston HE, Zhou P. Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Bioorg Med Chem Lett 2006;16:5953-5957.
168. Chan C, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chaudry L, Chung C-W, Convery MA, Hamblin JN, Johnstone L, Kelly HA, Kleanthous S, Patikis A, Patel C, Pateman AJ, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE, Whitworth C, Young RJ, Zhou P. Factor Xa Inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. J Med Chem 2007;50:1546-1557.
169. Young RJ, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chan C, Charbaut M, Chung C-w, Convery MA, Kelly HA, King NP, Kleanthous S, Mason AM, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE. Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with biaryl P4 motifs. Bioorg Med Chem Lett 2008;18:23-27.
170. Young RJ, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chan C, Charbaut M, Convery MA, Diallo H, Hortense E, Irving WR, Kelly HA, King NP, Kleanthous S, Mason AM, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE, Zhou P. Structure and property based design of factor Xa inhibitors: Biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. Bioorg Med Chem Lett 2008;18:28-33.
171. Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PYS, Quan ML. Sulfonamidolactam inhibitors of coagulation factor Xa. Bioorg Med Chem Lett 2008;18:2428-2433.
172. Bisacchi GS, Stein PD, Gougoutas JZ, Hartl KS, Lawrence RM, Liu E, Pudzianowski A, Schumacher WA, Sitkoff D, Steinbacher TE, Sutton J, Zhang ZM, Seiler S. Initial structure-activity relationships for a caprolactam-based series of neutral factor Xa inhibitors: Lead identification. Lett Drug Des Disc 2005;2:625-630.
173. Shi Y, Zhang J, Stein PD, Shi M, O'Connor SP, Bisaha SN, Li C, Atwal KS, Bisacchi GS, Sitkoff D, Pudzianowski AT, Liu EC, Hartl KS, Seiler SM, Youssef S, Steinbacher TE, Schumacher WA, Rendina AR, Bozarth JM, Peterson TL, Zhang G, Zahler R. Ketene aminal-based lactam derivatives as a novel class of orally active fXa inhibitors. Bioorg Med Chem Lett 2005;15:5453-5458.
174. Marsh N, Williams V. Practical applications of snake venom toxins in haemostasis. Toxicon 2005;45:1171-1181.
175. O'Connor SP, Atwal K, Li C, Liu ECK, Seiler SM, Shi M, Shi Y, Stein PD, Wang Y. Synthesis and evaluation of acylguanidine FXa inhibitors. Bioorg Med Chem Lett 2008;18:4696-4699.
176. Shi Y, Zhang J, Shi M, O'Connor SP, Bisaha SN, Li C, Sitkoff D, Pudzianowski AT, Chong S, Klei HE, Kish K, Yanchunas J, Jr, Liu ECK, Hartl KS, Seiler SM, Steinbacher TE, Schumacher WA, Atwal KS, Stein PD. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett 2009;19:4034-4041.
177. Shi Y, Sitkoff D, Zhang J, Klei HE, Kish K, Liu ECK, Hartl KS, Seiler SM, Chang M, Huang C, Youssef S, Steinbacher TE, Schumacher WA, Grazier N, Pudzianowski A, Apedo A, Discenza L, Yanchunas J, Stein PD, Atwal KS. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-Chloroindole-7-yl-based factor Xa inhibitors. J Med Chem 2008;51:7541-7551.
178. Faull AW, Mayo CM, Preston J, Stocker A. Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents. PCT Int Appl 1996; WO199610022.
179. Nishida H, Miyazaki Y, Kitamura Y, Ohashi M, Matsusue T, Okamoto A, Hosaka Y, Ohnishi S, Mochizuki H. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor. Chem Pharm Bull 2001;49:1237-1244.
180. Nishida H, Miyazaki Y, Mukaihira T, Saitoh F, Fukui M, Harada K, Itoh M, Muraoka A, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Ohnishi S, Mochizuki H. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors II. Substituent effect on biological activities. Chem Pharm Bull 2002;50:1187-1194.
181. Nishida H, Mukaihira T, Saitoh F, Harada K, Fukui M, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Shiromizu I, Ohnishi S, Mochizuki H. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3, 2-a]pyrazine-2(3H), 4'-piperidin]-5-one skeleton. Chem Pharm Bull 2004;52:406-412.
182. Nishida H, Miyazaki Y, Mukaihira T, Shimada H, Suzuki K, Saitoh F, Mizuno M, Matsusue T, Okamoto A, Hosaka Y, Matsumoto M, Ohnishi S, Mochizuki H. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition. Chem Pharm Bull 2004;52:459-462.
183. Bauer SM, Goldman EA, Huang W, Su T, Wang L, Woolfrey J, Wu Y, Zuckett JF, Arfsten A, Huang B, Kothule J, Lin J, May B, Sinha U, Wong PW, Hutchaleelaha A, Scarborough RM, Zhu B-Y. Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors. Bioorg Med Chem Lett 2004;14:4045-4050.
184. Ewing WR, Becker MR, Choi-Sledeski YM, Pauls HW, He W, Condon SM, Davis RS, Hanney BA, Spada AP, Burns CJ, Jiang JZ, Li A, Myers MR, Lau WF, Poli GB. Substituted piperazinone derivatives and other oxoazaheterocyclyl compounds useful as factor Xa inhibitors. PCT Int Appl 1999; WO199937304.
185. Maignan S, Guilloteau J-P, Choi-Sledeski YM, Becker MR, Ewing WR, Pauls HW, Spada AP, Mikol V. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket. J Med Chem 2003;46:685-690.
186. He W, Hanney B, Myers MR, Spada AP, Brown K, Colussi D, Chu V. Nonbenzamidine compounds as selective factor Xa inhibitors. Bioorg Med Chem Lett 2000;10:1737-1739.
187. He W, Hanney B, Myers MR, Condon S, Becker MR, Spada AP, Burns C, Brown K, Colussi D, Chu V. Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors. Bioorg Med Chem Lett 2002;12:919-922.
188. Choi-Sledeski YM, Kearney R, Poli G, Pauls H, Gardner C, Gong Y, Becker M, Davis R, Spada A, Liang G, Chu V, Brown K, Collussi D, Leadley R, Rebello S, Moxey P, Morgan S, Bentley R, Kasiewski C, Maignan S, Guilloteau JP, Mikol V. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J Med Chem 2003;46:681-684.
189. Jia ZJ, Su T, Zuckett JF, Wu Y, Goldman EA, Li W, Zhang P, Clizbe LA, Song Y, Bauer SM, Huang W, Woolfrey J, Sinha U, Arfsten AE, Hutchaleelaha A, Hollenbach SJ, Lambing JL, Scarborough RM, Zhu B-Y. N, N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors. Bioorg Med Chem Lett 2004;14:2073-2078.
190. Haginoya N, Kobayashi S, Komoriya S, Hirokawa Y, Furugori T, Nagahara T. Orally active factor Xa inhibitors: 4, 5, 6, 7-Tetrahydrothiazolo[5, 4-c]pyridine derivatives. Bioorg Med Chem Lett 2004;14:2935-2939.
191. Haginoya N, Kobayashi S, Komoriya S, Yoshino T, Suzuki M, Shimada T, Watanabe K, Hirokawa Y, Furugori T, Nagahara T. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4, 5, 6, 7-tetrahydrothiazolo[5, 4-c]pyridine as S4 binding element. J Med Chem 2004;47:5167-5182.
192. Komoriya S, Haginoya N, Kobayashi S, Nagata T, Mochizuki A, Suzuki M, Yoshino T, Horino H, Nagahara T, Suzuki M, Isobe Y, Furugoori T. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Bioorg Med Chem 2005;13:3927-3954.
193. Komoriya S, Kobayashi S, Osanai K, Yoshino T, Nagata T, Haginoya N, Nakamoto Y, Mochizuki A, Nagahara T, Suzuki M, Shimada T, Watanabe K, Isobe Y, Furugoori T. Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification. Bioorg Med Chem 2006;14:1309-1330.
194. Ishihara T, Seki N, Hirayama F, Orita M, Koshio H, Taniuchi Y, Sakai-Moritani Y, Iwatsuki Y, Kaku S, Kawasaki T, Matsumoto Y, Tsukamoto S-i. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors. Bioorg Med Chem 2007;15:4175-4192.
195. Imaeda Y, Miyawaki T, Sakamoto H, Itoh F, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. Bioorg Med Chem 2008;16:2243-2260.
196. Imaeda Y, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Discovery of piperazinylimidazo[1, 2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors. Bioorg Med Chem 2008;16:3125-3140.
197. Imaeda Y, Kuroita T, Sakamoto H, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Discovery of imidazo[1, 5-c]imidazol-3-ones: Weakly basic, orally active factor Xa inhibitors. J Med Chem 2008;51:3422-3436.
198. Herron DK, Goodson T, Wiley MR, Weir LC, Kyle JA, Yee YK, Tebbe AL, Tinsley JM, Mendel D, Masters JJ, Franciskovich JB, Sawyer JS, Beight DW, Ratz AM, Milot G, Hall SE, Klimkowski VJ, Wikel JH, Eastwood BJ, Towner RD, Gifford-Moore DS, Craft TJ, Smith GF. 1, 2-Dibenzamidobenzene inhibitors of human factor Xa. J Med Chem 2000;43:859-872.
199. 2-Aroylanthranilamide inhibitors of human factor Xa. J Med Chem 2000;43:873-882.
200. Wiley MR, Weir LC, Briggs S, Bryan NA, Buben J, Campbell C, Chirgadze NY, Conrad RC, Craft TJ, Ficorilli JV, Franciskovich JB, Froelich LL, Gifford-Moore DS, Goodson T, Herron DK, Klimkowski VJ, Kurz KD, Kyle JA, Masters JJ, Ratz AM, Milot G, Shuman RT, Smith T, Smith GF, Tebbe AL, Tinsley JM, Towner RD, Wilson A, Yee YK. Structure-based design of potent, amidine-derived inhibitors of factor Xa: Evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J Med Chem 2000;43:883-899.
201. Masters JJ, Franciskovich JB, Tinsley JM, Campbell C, Campbell JB, Craft TJ, Froelich LL, Gifford-Moore DS, Hay LA, Herron DK, Klimkowski VJ, Kurz KD, Metz JT, Ratz AM, Shuman RT, Smith GF, Smith T, Towner RD, Wiley MR, Wilson A, Yee YK. Non-amidine-containing 1, 2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity. J Med Chem 2000;43:2087-2092.
202. Franciskovich JB, Masters JJ, Tinsley JM, Craft TJ, Froelich LL, Gifford-Moore DS, Klimkowski VJ, Smallwood JK, Smith GF, Smith T, Towner RR, Weir LC, Wiley MR. Investigation of factor Xa inhibitors containing non-amidine S1 elements. Bioorg Med Chem Lett 2005;15:4838-4841.
203. Koshio H, Hirayama F, Ishihara T, Shiraki R, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Kaku S, Katayama N, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S-i. Synthesis and biological activity of novel 1, 2-disubstituted benzene derivatives as factor Xa inhibitors. Bioorg Med Chem 2005;13:1305-1323.
204. Zhang P, Bao L, Zuckett JF, Goldman EA, Jia ZJ, Arfsten A, Edwards S, Sinha U, Hutchaleelaha A, Park G, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu B-Y. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs. Bioorg Med Chem Lett 2004;14:983-987.
205. Zhang P, Bao L, Zuckett JF, Jia ZJ, Woolfrey J, Arfsten A, Edwards S, Sinha U, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu B-Y. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity. Bioorg Med Chem Lett 2004;14:989-993.
206. Zhang P, Bao L, Fan J, Jia ZJ, Sinha U, Wong PW, Park G, Hutchaleelaha A, Scarborough RM, Zhu B-Y. Anthranilamide-based N, N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR. Bioorg Med Chem Lett 2009;19:2186-2189
207. Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu B-Y. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 2009;19:2179-2185.
208. Turpie AGG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76.
209. Portola Pharmaceuticals initiates phase II trial of betrixaban, its novel oral factor Xa inhibitor for stroke prevention in atrial fibrillation. Portola Pharmaceuticals News Release November 3; 2009. Available at EXPLORE Xa Start.pdf (accessed July 29, 2009).
210. Shrader WD, Young WB, Sprengeler PA, Sangalang JC, Elrod K, Carr G. Neutral inhibitors of the serine protease factor Xa. Bioorg Med Chem Lett 2001;11:1801-1804.
211. Chou Y-L, Davey DD, Eagen KA, Griedel BD, Karanjawala R, Phillips GB, Sacchi KL, Shaw KJ, Wu SC, Lentz D, Liang AM, Trinh L, Morrissey MM, Kochanny MJ. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors. Bioorg Med Chem Lett 2003;13:507-511.
212. Kochanny MJ, Adler M, Ewing J, Griedel BD, Ho E, Karanjawala R, Lee W, Lentz D, Liang AM, Morrissey MM, Phillips GB, Post J, Sacchi KL, Sakata ST, Subramanyam B, Vergona R, Walters J, White KA, Whitlow M, Ye B, Zhao Z, Shaw KJ. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa. Bioorg Med Chem 2007;15:2127-2146.
213. Ye B, Arnaiz DO, Chou YL, Griedel BD, Karanjawala R, Lee W, Morrissey MM, Sacchi KL, Sakata ST, Shaw KJ, Wu SC, Zhao Z, Adler M, Cheeseman S, Dole WP, Ewing J, Fitch R, Lentz D, Liang A, Light D, Morser J, Post J, Rumennik G, Subramanyam B, Sullivan ME, Vergona R, Walters J, Wang YX, White KA, Whitlow M, Kochanny MJ. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem 2007;50:2967-2980.
214. Mendel D, Marquart AL, Joseph S, Waid P, Yee YK, Tebbe AL, Ratz AM, Herron DK, Goodson T, Masters JJ, Franciskovich JB, Tinsley JM, Wiley MR, Weir LC, Kyle JA, Klimkowski VJ, Smith GF, Towner RD, Froelich LL, Buben J, Craft TJ. Anthranilamide inhibitors of factor Xa. Bioorg Med Chem Lett 2007;17:4832-4836.
215. Corte JR, Fang T, Pinto DJP, Han W, Hu Z, Jiang X-J, Li Y-L, Gauuan JF, Hadden M, Orton D, Rendina AR, Luettgen JM, Wong PC, He K, Morin PE, Chang C-H, Cheney DL, Knabb RM, Wexler RR, Lam PYS. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties. Bioorg Med Chem Lett 2008;18:2845-2849.
216. Qiao JX, Chang C-H, Cheney DL, Morin PE, Wang GZ, King SR, Wang TC, Rendina AR, Luettgen JM, Knabb RM, Wexler RR, Lam PYS. SAR and X-ray structures of enantiopure 1, 2-cis-(1R, 2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation factor Xa. Bioorg Med Chem Lett 2007;17:4419-4427.
217. Qiao JX, Wang TC, Wang GZ, Cheney DL, He K, Rendina AR, Xin B, Luettgen JM, Knabb RM, Wexler RR, Lam PYS. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. Bioorg Med Chem Lett 2007;17:5041-5048.
218. Nagata T, Yoshino T, Haginoya N, Yoshikawa K, Isobe Y, Furugohri T, Kanno H. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors. Bioorg Med Chem Lett 2007;17:4683-4688.
219. Mochizuki A, Nakamoto Y, Naito H, Uoto K, Ohta T. Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor. Bioorg Med Chem Lett 2008;18:782-787.
220. Nagata T, Yoshino T, Haginoya N, Yoshikawa K, Nagamochi M, Kobayashi S, Komoriya S, Yokomizo A, Muto R, Yamaguchi M, Osanai K, Suzuki M, Kanno H. Discovery of N-[(1R, 2S, 5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4, 5, 6, 7-tetrahydrothiazolo[5, 4-c]pyridine-2-carboxamide hydrochloride: A novel, potent and orally active direct inhibitor of factor Xa. Bioorg Med Chem 2009;17:1193-1206.
221. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T. DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J Thromb Haemost 2008;6:1542-1549.
222. Raskob G, Cohen A, Eriksson B, Macdonald A, Puskas D, Shi M, Verho M, Weitz J. Randomized double-blind multi-dose trial of the oral factor-Xa inhibitor DU-176b versus LMW heparin (dalteparin) for prevention of venous thromboembolism after total hip replacement. Poster 3712. Annual Congress, European Society of Cardiology. Munich, Germany, 2008. Available at (Accessed July 27, 2009).
223. Fuji T, Fujita S, Tachibana S, Kawai Y. Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty. Am Soc Hematol Ann Meet Abstracts 2008;112:Abs 34.
224. Daiichi Sankyo initiates phase III trial of its investigational factor Xa inhibitor, DU-176b, in patients with atrial fibrillation. Daiichi Sankyo Co, Ltd News Release Dec 7, 2008. Available at initiates phase III trial of DU-176b.pdf (Accessed July 24, 2009).
225. Gabriel B, Stubbs MT, Bergner A, Hauptmann J, Bode W, Sturzebecher J, Moroder L. Design of benzamidine-type inhibitors of factor Xa. J Med Chem 1998;41:4240-4250.
226. Schweinitz A, Sturzebecher A, Sturzebecher U, Schuster O, Sturzebecher J, Steinmetzer T. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: Part 1. Med Chem 2006;2:349-361.
227. Stürzebecher A, Dönnecke D, Schweinitz A, Schuster O, Steinmetzer P, Stürzebecher U, Kotthaus J, Clement B, Stürzebecher J, Steinmetzer T. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: Part 2. ChemMedChem 2007;2:1043-1053.
228. Dönnecke D, Schweinitz A, Stürzebecher A, Steinmetzer P, Schuster M, Stürzebecher U, Nicklisch S, Stürzebecher J, Steinmetzer T. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorg Med Chem Lett 2007;17:3322-3329.
229. Jones SD, Liebeschuetz JW, Morgan PJ, Murray CW, Rimmer AD, Roscoe JME, Waszkowycz B, Welsh PM, Wylie WA, Young SC, Martin H, Mahler J, Brady L, Wilkinson K. The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa. Bioorg Med Chem Lett 2001;11:733-736.
230. Sheehan SM, Masters JJ, Wiley MR, Young SC, Liebeschuetz JW, Jones SD, Murray CW, Franciskovich JB, Engel DB, Weber WW, Marimuthu J, Kyle JA, Smallwood JK, Farmen MW, Smith GF. A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors. Bioorg Med Chem Lett 2003;13:2255-2259.
231. Klimkowski VJ, Watson BM, Wiley MR, Liebeschuetz J, Franciskovich JB, Marimuthu J, Bastian JA, Sall DJ, Smallwood JK, Chirgadze NY, Smith GF, Foster RS, Craft T, Sipes P, Chastain M, Sheehan SM. D-Phenylglycinol-derived non-covalent factor Xa inhibitors: Effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity. Bioorg Med Chem Lett 2007;17:5801-5805.
232. Franciskovich JB, Masters JJ, Weber WW, Klimkowski VJ, Chouinard M, Sipes PR, Johnson LM, Snyder DW, Chastain MK, Craft TJ, Towner RD, Gifford-Moore DS, Froelich LL, Smallwood JK, Foster RS, Smith GF, Liebeschuetz JW, Murray CW, Young SC. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors. Bioorg Med Chem Lett 2007;17:6910-6913.
233. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007;5:746-753.
234. Kohrt JT, Filipski KJ, Cody WL, Bigge CF, La F, Welch K, Dahring T, Bryant JW, Leonard D, Bolton G, Narasimhan L, Zhang E, Peterson JT, Haarer S, Sahasrabudhe V, Janiczek N, Desiraju S, Hena M, Fiakpui C, Saraswat N, Sharma R, Sun S, Maiti SN, Leadley R, Edmunds JJ. The discovery of glycine and related amino acid-based factor Xa inhibitors. Bioorg Med Chem 2006;14:4379-4392.
235. Van Huis CA, Bigge CF, Casimiro-Garcia A, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Narasimhan LS, Schaum RP, Zhang E, Bryant JW, Haarer S, Janiczek N, Leadley RJ, Jr, McClanahan T, Peterson JT, Welch KM, Edmunds JJ. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors. Chem Biol Drug Des 2007;69:444-450.
236. Kohrt JT, Bigge CF, Bryant JW, Casimiro-Garcia A, Chi L, Cody WL, Dahring T, Dudley DA, Filipski KJ, Haarer S, Heemstra R, Janiczek N, Narasimhan L, McClanahan T, Peterson JT, Sahasrabudhe V, Schaum R, Van-Huis CA, Welch KM, Zhang E, Leadley RJ, Edmunds JJ. The discovery of (2R, 4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1, 2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007;70:100-112.
237. Van Huis CA, Casimiro-Garcia A, Bigge CF, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Leadley RJ Jr, Narasimhan LS, McClanahan T, Mochalkin I, Pamment M, Thomas Peterson J, Sahasrabudhe V, Schaum RP, Edmunds JJ. Exploration of 4, 4-disubstituted pyrrolidine-1, 2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action. Bioorg Med Chem 2009;17:2501-2511.
238. Klein SI, Czekaj M, Gardner CJ, Guertin KR, Cheney DL, Spada AP, Bolton SA, Brown K, Colussi D, Heran CL, Morgan SR, Leadley RJ, Dunwiddie CT, Perrone MH, Chu V. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J Med Chem 1998;41:437-450.
239. 4 and side-chain modifications for improved in vitro potency. Bioorg Med Chem Lett 2002;12:1667-1670.
240. Guertin KR, Gardner CJ, Klein SI, Zulli AL, Czekaj M, Gong Y, Spada AP, Cheney DL, Maignan S, Guilloteau J-P, Brown KD, Colussi DJ, Chu V, Heran CL, Morgan SR, Bentley RG, Dunwiddie CT, Leadley RJ, Pauls HW. Optimization of the b-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity. Bioorg Med Chem Lett 2002;12:1671-1674.
241. Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby J-F, Saaiman J, Simek S, De Swart J. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary ntervention: The SEPIA-PCI trial. Circulation 2007;115:2642-2651.
242. Guertin KR, Choi Y-M. The discovery of the factor Xa inhibitor otamixaban: From lead identification to clinical development. Curr Med Chem 2007;14:2471-2481.
243. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor. J Med Chem 2005;48:5900-5908.
244. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet 2008;372:31-39.
245. Buller HR, Lensing AWA, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT dose-ranging study. Blood 2008;112:2242-2247.
246. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775.
247. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786.
248. Siddique A, Lip GYH, Shantsila E. Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation. Therapy 2009;6:187-189.
249. Shi Y, Sitkoff D, Zhang J, Han W, Hu Z, Stein PD, Wang Y, Kennedy LJ, O'Connor SP, Ahmad S, Liu ECK, Seiler SM, Lam PYS, Robl JA, Macor JE, Atwal KS, Zahler R. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors. Bioorg Med Chem Lett 2007;17:5952-5958.